Ranbaxy consolidates presence in Dermatology Segment

Acquires Brands from Ochoa Laboratories Ltd

Ranbaxy Laboratories Limited (Ranbaxy), announced today that it has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories Limited (Ochoa) for its entire range of Dermatological and Lifestyle products. The acquired brands command considerable equity with doctors and are market leaders in their respective categories. They complement Ranbaxy’s existing derma portfolio. The products enjoy high margins because of their novelty and brand appeal and will be initially marketed in India.

Commenting on the acquisition, Mr. Malvinder Mohan Singh, Chairman, CEO & MD, Ranbaxy, said, “The move strengthens  Ranbaxy’s domestic presence and market share in Deramatology, a high-growth therapeutic segment, for the company. I believe, the Indian pharmaceutical space is ripe for consolidation and Ranbaxy’s intent is to accelerate this trend with a view to reach commanding positions, especially in the high value chronic and acute therapy areas”.

Sanjeev Dani, Senior Vice President & Regional Director, Asia & CIS, Ranbaxy, said, “ Given Ranbaxy’s extensive distribution capability, we are best positioned to leverage the vast potential of these brands while consolidating our product portfolio in Dermatology.”

The current market size of the Dermatology segments in India is approximately Rs. 1950 crores, growing rapidly at  about11%.

Ranbaxy already has a strong presence in the dermatology market including steroids with products such as Zole-F, Suncros, Efflora, Fucidin  and Teczine, among others.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries.